drugset / Trial / NCT06257394
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Phase 2
Recruiting
74 enrolled
Hyoung Jin Kang
Asan Medical Center · collabPusan National University Yangsan Hospital · collabSamsung Medical Center · collabSeoul St. Mary's Hospital · collabSeverance Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Very high-risk acute lymphoblastic leukemia
Timeline
- Start
- 2024-10-20
- Primary completion
- 2034-12-31
- Completion
- 2034-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | — | — |